Effectiveness and safety of first-line nivolumab–ipilimumab in metastatic renal cell carcinoma

Miguel Escario Gómez, Macarena García-Trevijano Cabetas, Clara Herranz Muñoz, María Gema Casado Abad, Luis Sánchez Rubio-Ferrández, Alicia Herrero Ambrosio, Department of Hospital Pharmacy, Hospital Universitario La Paz

Journal of Oncology Pharmacy Practice

Published online on April 13, 2026

Abstract

Journal of Oncology Pharmacy Practice, Ahead of Print.
Background/AimThe combination of nivolumab and ipilimumab is the standard first-line treatment for patients with metastatic renal cell carcinoma (mRCC) of intermediate or poor IMDC risk. However, real-world data in unselected populations remain limited. ...